Coeptis Therapeutics Files 8-K: Accountant Change & Financials
Ticker: COEPW · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1759186
Sentiment: neutral
Topics: accountant-change, financial-statements, exhibits
Related Tickers: COEP
TL;DR
Coeptis Therapeutics (COEP) filed an 8-K on 9/30/24, reporting a change in their accountant and filing financial exhibits.
AI Summary
On September 30, 2024, Coeptis Therapeutics Holdings, Inc. filed an 8-K report. The filing primarily concerns changes in the registrant's certifying accountant and includes financial statements and exhibits. The company, formerly known as Bull Horn Corp., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing signals a change in the company's auditing firm, which can impact financial reporting transparency and investor confidence. It also provides updated financial information.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of administrative and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- Coeptis Therapeutics Holdings, Inc. (company) — Registrant
- Bull Horn Corp. (company) — Former company name
- September 30, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report changes in the registrant's certifying accountant and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 30, 2024.
What was Coeptis Therapeutics Holdings, Inc. formerly known as?
Coeptis Therapeutics Holdings, Inc. was formerly known as Bull Horn Corp.
In which state is Coeptis Therapeutics Holdings, Inc. incorporated?
Coeptis Therapeutics Holdings, Inc. is incorporated in Delaware.
What is the business address of Coeptis Therapeutics Holdings, Inc.?
The business address of Coeptis Therapeutics Holdings, Inc. is 105 Bradford Road, Suite 420, Wexford, PA 15090.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 14.3 · Accepted 2024-09-30 16:30:08
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share COEP Nasdaq Capital Mark
- $11.50 — e-half of one share of Common Stock for $11.50 per whole share COEPW Nasdaq Capita
Filing Documents
- coeptis_8k.htm (8-K) — 34KB
- coeptis_ex1601.htm (EX-16.1) — 3KB
- image_004.jpg (GRAPHIC) — 8KB
- image_005.jpg (GRAPHIC) — 11KB
- 0001683168-24-006763.txt ( ) — 284KB
- coep-20240930.xsd (EX-101.SCH) — 3KB
- coep-20240930_def.xml (EX-101.DEF) — 29KB
- coep-20240930_lab.xml (EX-101.LAB) — 36KB
- coep-20240930_pre.xml (EX-101.PRE) — 26KB
- coeptis_8k_htm.xml (XML) — 5KB
01 Change in Registrant's Certifying Accountant
Item 4.01 Change in Registrant's Certifying Accountant. On September 24, 2024, with the approval of the Audit Committee of the Company and the approval of the Board of Directors of the Company, the Company engaged Astra Audit & Advisory, LLC ("Astra") as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024, effective immediately. The Company dismissed Turner, Stone & Company, LLP ("Turner") as the Company's independent registered public accounting firm. With the exception of a "going concern" explanatory paragraph, Turner's audit reports on the Company's consolidated financial statements as of and for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. During the fiscal years ended December 31, 2022 and 2023, and the subsequent interim periods through September 24, 2024, there were (i) no disagreements (as described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Turner on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Turner's satisfaction, would have caused Turner to make reference thereto in their reports on the financial statements for such years, and (ii) no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K. The Company provided Turner with a copy of the disclosures it is making in this Current Report on Form 8-K in response to Item 304(a) of Regulation S-K and requested that Turner furnish a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the statements made herein. A copy of Turner's letter dated September 30, 2024 is filed as Exhibit 16.1 hereto. During the fiscal years ended December 31, 2022, and 2023, and the subsequent interi
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No . Description 16.1 Letter of Turner, Stone & Company, LLP dated September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Coeptis Therapeutics Holdings, Inc. Date: September 30, 2024 By: /s/ David Mehalick David Mehalick Chief Executive Officer 3